AbbVie (NYSE:ABBV) Trading Down 2.4% – Should You Sell?

AbbVie Inc. (NYSE:ABBV)’s stock price was down 2.4% during trading on Thursday . The company traded as low as $215.83 and last traded at $216.6550. Approximately 6,154,733 shares were traded during mid-day trading, a decline of 17% from the average daily volume of 7,418,281 shares. The stock had previously closed at $221.89.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Zacks Research nudged up multiple near‑term and FY2026–FY2027 EPS estimates for AbbVie, a signal that analysts expect stronger earnings momentum into upcoming quarters. Zacks: AbbVie stock dips — key facts
• Positive Sentiment: AbbVie is expanding its oncology pipeline — it kicked off a first‑in‑human ABBV‑711 trial in advanced squamous tumors, which supports long‑term revenue diversification beyond immunology. TipRanks: ABBV starts ABBV‑711 trial
• Positive Sentiment: AbbVie continues to advance new categories: completion of first‑in‑human work on an obesity candidate (GUB014295) and other early‑stage programs suggest multiple future growth avenues. TipRanks: obesity pipeline update
• Positive Sentiment: Skyrizi again led full‑year TV ad spending — heavy, sustained marketing should support continued uptake and revenue growth for one of AbbVie’s growth drivers. FiercePharma: Skyrizi top TV ad spender
• Neutral Sentiment: AbbVie issued a topline release for epcoritamab (DuoBody CD3xCD20) from the Phase‑3 EPCORE DLBCL‑1 trial and said it will engage global regulators to discuss next steps — company statement, not a definitive approval path. PR Newswire: AbbVie topline EPCORE DLBCL‑1
• Negative Sentiment: Several market reports characterize the EPCORE readout as a clinical disappointment on survival endpoints (despite PFS signals), which triggered selling pressure in partner Genmab and put near‑term oncology upside at risk for AbbVie. That mixed/missed survival messaging is the primary reason for today’s share weakness. Seeking Alpha: Genmab down after Epkinly trial data

Wall Street Analyst Weigh In

Several analysts have commented on ABBV shares. DZ Bank downgraded AbbVie from a “buy” rating to a “hold” rating and set a $237.00 price objective for the company. in a research note on Tuesday, November 4th. Guggenheim upped their price target on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Morgan Stanley lifted their price objective on shares of AbbVie from $261.00 to $269.00 and gave the company an “overweight” rating in a research report on Friday, December 12th. Evercore ISI upped their price objective on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research report on Monday, September 22nd. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research note on Wednesday, October 8th. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company’s stock. According to data from MarketBeat, AbbVie presently has an average rating of “Moderate Buy” and an average price target of $247.84.

AbbVie Stock Performance

The stock’s fifty day moving average price is $226.80 and its 200-day moving average price is $216.28. The firm has a market cap of $378.89 billion, a PE ratio of 162.41, a P/E/G ratio of 0.89 and a beta of 0.36.

AbbVie (NYSE:ABBV) last issued its earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, topping the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The firm’s revenue for the quarter was up 9.1% compared to the same quarter last year. During the same period in the prior year, the business posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Sell-side analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be given a $1.73 dividend. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.2%. The ex-dividend date is Friday, January 16th. AbbVie’s dividend payout ratio (DPR) is 496.97%.

Hedge Funds Weigh In On AbbVie

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Conning Inc. boosted its stake in shares of AbbVie by 7.1% in the second quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after buying an additional 12,690 shares during the period. Diversified Trust Co raised its holdings in AbbVie by 23.6% in the 3rd quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after acquiring an additional 10,891 shares in the last quarter. Dohj LLC raised its holdings in AbbVie by 41.8% in the 2nd quarter. Dohj LLC now owns 4,529 shares of the company’s stock valued at $802,000 after acquiring an additional 1,335 shares in the last quarter. Permanent Capital Management LP bought a new stake in shares of AbbVie during the 3rd quarter valued at $720,000. Finally, Railway Pension Investments Ltd grew its holdings in shares of AbbVie by 33.0% during the 3rd quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after purchasing an additional 211,800 shares in the last quarter. Institutional investors and hedge funds own 70.23% of the company’s stock.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.